New insider activity at United Therapeutics ( (UTHR) ) has taken place on May 13, 2025.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Director Tommy Thompson has recently sold 2,500 shares of United Therapeutics stock, amounting to a total transaction value of $762,850.
Recent Updates on UTHR stock
In the last 24 hours, United Therapeutics experienced significant developments impacting its stock. Argus lowered its price target for United Therapeutics from $375 to $345, maintaining a Buy rating. This adjustment reflects the company’s ongoing advancements in organ development, particularly the FDA clearance for a clinical study of its investigational UKidney, a xenokidney from a pig with 10 gene edits. Despite this, the company shows strong performance in its Tyvaso franchise and other products, suggesting potential stock price upside. United Therapeutics reported a robust Q1 2025 financial performance, with a 17% increase in total revenues driven by increased sales of Tyvaso DPI and other key products. The company also secured a $2.5 billion credit facility to refinance existing debt and support corporate purposes. However, challenges in xenotransplantation and competitive pressures in the pulmonary arterial hypertension market remain concerns. Overall, the company’s strategic advancements and positive regulatory feedback contribute to a positive outlook, despite the competitive landscape and technical sentiment indicating a Sell signal.
Spark’s Take on UTHR Stock
According to Spark, TipRanks’ AI Analyst, UTHR is a Outperform.
United Therapeutics presents a robust financial and strategic position with strong revenue growth, profitability, and strategic investments supporting long-term prospects. Technical indicators suggest stability, while valuation remains reasonable. The positive earnings call underscores the company’s capacity for sustained growth despite competitive challenges, leading to a favorable overall score.
To see Spark’s full report on UTHR stock, click here.
More about United Therapeutics
YTD Price Performance: -16.32%
Average Trading Volume: 515,459
Technical Sentiment Signal: Buy
Current Market Cap: $13.6B